56515-89-0

Basic information

• Product Name: 1-CARBETHOXYAZEPAN-4-ONE
• Synonyms: 1-CARBETHOXYAZEPAN-4-ONE;1H-Azepine-1-carboxylic acid, hexahydro-4-oxo-, ethyl ester;4-Oxoazepane-1-carboxylic Acid Ethyl Ester;Ethyl 4-Oxoazepane-1-carboxylate;Hexahydro-4-oxo-1H-azepine-1-carboxylic Acid Ethyl Ester;ethyl hexahydro-4-oxo-1H-azepine-1-carboxylate
• CAS NO: 56515-89-0
• Molecular Formula: C₉H₁₅NO₃
• Molecular Weight: 185.22
• Product Categories: Miscellaneous Reagents
• Mol File: 56515-89-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform, DMSO, Ethanol
• CAS DataBase Reference: 1-CARBETHOXYAZEPAN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CARBETHOXYAZEPAN-4-ONE(56515-89-0)
• EPA Substance Registry System: 1-CARBETHOXYAZEPAN-4-ONE(56515-89-0)

Safety Data

• Hazardous Substances Data: 56515-89-0(Hazardous Substances Data)

Usage

Description

1-Carbethoxyazepan-4-one, with the CAS number 56515-89-0, is a chemical compound that is characterized as a colorless oil. It is primarily utilized in the field of organic synthesis, serving as a valuable building block for the creation of various complex organic molecules.

Uses

Used in Organic Synthesis:
1-Carbethoxyazepan-4-one is used as a synthetic intermediate for the development of a wide range of organic compounds. Its application in this field is due to its unique chemical structure, which allows for further functionalization and the formation of more complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-Carbethoxyazepan-4-one is used as a key component in the synthesis of various drugs. Its versatility in organic synthesis enables the development of new therapeutic agents with potential applications in treating different medical conditions.
Used in Chemical Research:
1-Carbethoxyazepan-4-one also finds application in chemical research, where it is employed as a model compound to study various reaction mechanisms and to develop new synthetic methodologies. This contributes to the advancement of chemical knowledge and the discovery of novel chemical processes.

Upstream product

• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 623-73-4 diazoacetic acid ethyl ester 
• 19786-58-4 5-oxoazepane-1,4-dicarboxylic acid diethyl ester 
• 50492-22-3 azepan-4-one hydrochloride 
• 541-41-3 chloroformic acid ethyl ester 
• 105416-56-6 1-aza-5-oxocycloheptane 

Downstream Products

• 1621910-44-8 (R)-ethyl 4-(tosyloxy)azepane-1-carboxylate 
• 1621910-38-0 C₁₆H₂₃NO₃ 
• 1621910-37-9 C₁₆H₂₃NO₃ 
• 1621910-36-8 ethyl 4-(benzyloxy)azepane-1-carboxylate 
• 1116680-28-4 C₁₅H₂₁NO₃ 
• 143943-98-0 1-<2-(1-hydroxy-1-phenyl)ethyl>-4-(propananilido)perhydroazepine 
• 143943-96-8 1-<2-(1-hydroxy-1-phenyl)ethyl>-4-anilinoperhydroazepine 
• 143943-97-9 1-<2-(1-propoxy-1-phenyl)ethyl>-4-(propananilido)perhydroazepine 
• 143943-99-1 1-carbethoxy-4-(propananilido)perhydroazepine 
• 143944-00-7 4-(propananilido)perhydroazepine 
• 74134-10-4 (1-Phenethyl-azepan-4-yl)-phenyl-amine 
• 74156-55-1 (1-Allyl-azepan-4-yl)-phenyl-amine 
• 74134-11-5 (1-Cyclopropylmethyl-azepan-4-yl)-phenyl-amine 
• 74134-08-0 (1-Methyl-azepan-4-yl)-phenyl-amine 

Relevant articles and documents

OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR

This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic Μ1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.

The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors

Discovery of a series of azepine sulfonamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is described. SAR studies at the 4-position of the azepane ring have resulted in the discovery of a very potent compound 30 which has

COMPOUND

There is provided a compound having Formula (I) wherein each of R1, R2, R4, R5, R6 and R7 are independently selected from (a) H, (b) R17, -OC(R17)3, -OCH(R17)2, -(OCH2R)17, -C(R17)3, -CH(R17)2, or -CH2R17 wherein R17 is a halogen; (c) -CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f) optionally substituted aryl; (g) optionally substituted heteroaryl; (h) optionally substituted arylalkyl; (i) optionally substituted heteroarylalkyl; (j) hydroxy; (k) alkoxy; (l) aryloxy; (m) -SO2-alkyl; and (n) -N(R11)C(O)R13; wherein the optional substituents of (d) (e) (f) (h) and (i) are selected from the group consisting of: C1-6 alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl ; each of rings A and B are selected from five or six membered carbon rings optionally containing one or more hetero atoms selected from N, S, and O and optionally having fused thereto a further ring; X is an optional group selected from O, S, S=O, S(=O)2, C=O, S(=O)2NR8, C=ONR9, NR10, wherein R8, R9 and R10 are independently selected from H and hydrocarbyl, wherein n and p are independently selected from O and 1 ; Y is (R11)1-3 wherein each R11 is independently selected from NR12, CR13R14, S(=O)2 and C=O, wherein R12, R13 and R14 are independently selected from H and hydrocarbyl; Z is selected from (i) six or seven membered ring containing carbon and at least one nitrogen, which may be optionally substituted wherein the substituents may together form further ring fused thereto; and (ii) a -R15-NR16- group wherein R15 is an optionally substituted C1-6 alkyl chain and R16 is selected from H and hydrocarbyl; and R3 is selected from Formula (A).